Price
Target price
€1.85
€1.85
1.090%
0.02
1.090%
-
06.02.23 / Frankfurt
WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cerenis Therapeutics Holding S.A. Stock
There is an upward development for Cerenis Therapeutics Holding S.A. compared to yesterday, with an increase of €0.020 (1.090%).
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | 1.090% | 1.422% | 4.864% | -14.167% | 10.095% | 362.921% | -4.236% |
| Genomic Vision S.A. | 29.030% | 31.868% | -56.204% | -92.941% | -36.508% | -97.598% | -99.587% |
| Sensorion SA | -0.860% | 3.288% | 0.729% | -47.810% | 6.966% | -60.514% | - |
| Hybrigenics S.A. | 19.170% | 10.017% | 23.408% | -47.698% | 31.537% | -41.161% | -88.638% |
News
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the
